Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Charles River Laboratories disclosures can feel like running a full toxicology study—dense tables on research models, acquisition earn-outs, and animal welfare compliance stretch across hundreds of pages. If you have ever wondered, “Where can I see Charles River Laboratories insider trading Form 4 transactions before the market reacts?” you are not alone.
Stock Titan’s AI turns that complexity into clarity. Our engine delivers Charles River Laboratories SEC filings explained simply, flagging what moves the needle in real time. Whether it’s a Charles River Laboratories quarterly earnings report 10-Q filing or an 8-K on a sudden facility shutdown, you receive instant context alongside the source document.
- 10-K & 10-Q – Backlog trends, segment margins, and R&D spend with Charles River Laboratories earnings report filing analysis.
- Form 4 – Track Charles River Laboratories Form 4 insider transactions real-time to spot management’s conviction.
- Proxy (DEF 14A) – Quickly surface Charles River Laboratories proxy statement executive compensation details without scrolling through legal prose.
- 8-K – Material events such as contract wins or biosecurity updates are offered as Charles River Laboratories 8-K material events explained.
Every filing arrives within minutes of hitting EDGAR, paired with AI-powered summaries, keyword search, and historical comparisons. Use cases span monitoring Charles River Laboratories executive stock transactions Form 4, evaluating acquisition synergies, or simply understanding Charles River Laboratories SEC documents with AI. Stop wading through PDF labyrinths; start focusing on decisions that matter.
Form 144 filing for Charles River Laboratories International, Inc. (CRL) discloses a planned sale of 4,000 common shares through Merrill Lynch, valued at $550,000. The filer expects the transaction to occur on or about 06/23/2025. Total shares outstanding are reported at 49,115,712, so the proposed sale represents roughly 0.008% of the public float. The shares being sold were acquired on 06/02/2025 via an open-market purchase and will be settled for cash. No prior sales were reported in the past three months, and the form contains no remarks indicating special circumstances. The identity of the filer, their relationship to CRL, and any 10b5-1 plan details were not provided.
The filing is a routine notice of intent required under Rule 144 and does not, by itself, finalize the sale. Given the relatively small size versus market capitalization and the absence of additional context, the disclosure is likely to have limited market impact.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
What is the primary focus of Charles River Labs Intl Inc?
Which industries does CRL primarily serve?
How does Charles River Labs generate revenue?
What sets CRL apart from its competitors?
How does CRL support the drug development process?
What role does quality assurance play in CRL's operations?
Can CRL assist with both early-stage and advanced research?
How does the company address regulatory compliance in its services?
